BillionToOne, Inc Investor Event Transcript, Nov 10, 2026
BillionToOne, Inc. (BLLN)
Billion to One CEO Ozan Atay said a head-to-head study detected 50% more actionable therapies, oncology test volumes were growing faster than 100% year over year, and prenatal could sustain about 20% growth. AI summary
Conference Transcript - BLLN 2026-11-10
Doug Schenkel, Analyst — UBS
All right. Good afternoon. I'm Doug Schenkel with UBS, and it's my pleasure to welcome Okazan Atay, co-founder and chief executive officer of Billion to One. Thank you for being here. I appreciate you making the trip. So Billion to One brings a compelling scientific foundation to important clinical questions, from prenatal screening with Unity to cancer care with North Star. Lots to talk about, lots of exciting things going on in the company. Today, what we're going to do is we're really going to explore the growth runway, adoption, and really the balance between investment in growth, investment in science, and profitability. In terms of just, you know, essentially the discussion arc for today, I want to spend some time on platform differentiation. I want to talk a little bit about the quarter. Then we'll go product category by product category. So we'll go Unity, North Star, and then we'll wrap up with some financials. So that's the roadmap. Just to start off, high level, what unmet need inspired Billion to One? What inspired you to advance the science, advance the technology, and where does the QCT backbone that supports precise quantification create the greatest clinical and economic advantage relative to other solutions that are out there?
Ozan Atay, CEO
Self-free DNA is a truly remarkable biomarker. It is the microcosm of the entire body, but it is also a very rare entity biomarker. And what we realized was that You know, as a scientist, we were seeing how, you know, maybe for the first time, an academic idea can turn into a very impactful clinical outcome very quickly. I was at Stanford, and looking at the evolution of cell-free DNA field, you know, seeing firsthand how an academic research can impact. You know, millions of lives changed standards of care. We started looking into, you know, what more cell-free DNA can be used for. We realized that the most common genetic disorders in the world are not, you know, trisomies are not Down syndrome or aneuploidies. They are, you know, these single gene conditions, and in particular sickle cell disease and beta thalassemia. And we realize that to be able to detect sickle cell disease and beta thalassemia and other single-gene conditions directly from a maternal blood sample, you have to get down to single-molecule-level sensors. And you need to remove all sorts of other noise. So, you know, that is what QCT technology allows us to do. But, of course, as soon as we built the technology, we knew how it would be transformative, not just for prenatal testing, but across the board for cell-free DNA testing. You know, it can unlock tremendous... Clinical value, especially as the problems become more difficult, as we go from, you know, large chromosomal abnormalities to single gene conditions, and from late stage cancers to, you know, early stage cancers and even early detection, the problem is no longer the signal. The problem is the noise. And we see this from, you know, actually the different approaches that different companies take to these more difficult technical problems. So if you are looking at, you know, something that is 0.01% of the total DNA or lower. It is no longer about trying to sequence more. It's no longer about trying to look at more and more locations, because you are not limited by the signal. You are limited by the noise that that process brings in. And that is why, regardless of what approaches that the others are taking, if you look at the clinical results for tissue-free MRD or early detection. Performances are very similar, and they are not enough. They are not at the levels that we want them to be for them to be truly standard of care. And this is where I think QCTs, by being able to reduce the noise, allows us to tackle those clinical problems that no brute force and let sequence as much as possible approach can solve. In simpler problems, it allows us to have, you know, Industry-leading, you know, low level of COGS. So the advantage of QCT technology, when we are solving a problem that another methodology can solve, for instance, either directly or indirectly, the COGS of solving it in other ways is going to be substantially higher than what we can do it for. But as we go into more and more difficult problems, especially in cancer, it's not even just a COGS question. It becomes much more of a capability question.
Doug Schenkel, Analyst — UBS
Right. Differences in limit of detection, the resolution that you can look at things with. You know, it's interesting. In a different discussion earlier today, you know, You know, and again, I'm not a scientist, but I've looked at a lot of papers. I play one on TV now. But when you look at a lot of the cell-free DNA approaches, you do start to see certain areas where some of the technologies that have been advanced, some of the more traditional approaches, if you can talk about it that way, given we're still at a pretty early stage in the industry. But the biology does seem to lead you to sort of the same conclusions in terms of what the limit of what you can do is toggling between sensitivity and specificity. What you're describing is an approach that obviously, because of how it treats noise, can basically do better than those approaches. But it does seem like some of those approaches are hitting their ceiling. It doesn't sound like you feel like you're at a point where you're hitting the limit of what you can do with your approach factoring in the biology. Is that fair?
Ozan Atay, CEO
That's fair. I mean, if you think about, you know, tumor-informed MRD as a category, you know, why does anyone do tumor-informed MRD? The concept of tumor-informed MRD is that when you sequence the cell-free DNA, you see real mutations, but you see all sorts of PCR errors, amplification errors, sequencing errors. It becomes very difficult to differentiate what is real or what is not. Right. That is the sensitivity specificity trade-off in tissue-free MRD and early detection. Right? If you call them, your sensitivity increases, but your specificity decreases. And that is why, you know, there are so many more tumor-informed approaches, because it solves the noise problem. If you sequence the tissue to begin with... Now you know which mutations are real, so you can just look at those mutations in cell-free DNA. But of course, you know, tumor-informed MRD has logistical challenges, you know, other problems. Of course, you can't do tumor-informed, you know, early detection.
Doug Schenkel, Analyst — UBS
Right, right.
Ozan Atay, CEO
You know, you need to do it in a tissue-free manner, and this is where, you know, our technology, I think, is going to shine the most, because we don't even have to compete with the tumor-informed approaches.
Doug Schenkel, Analyst — UBS
One more high-level question, and this is really interesting. So we've talked about, and we're going to go into more detail, about your journey in reproductive health, your advancements in cancer. However, with this approach, logically, there's other areas you could participate in the long term. Again, you got a lot to work with what you have now, but the QCT, the approach, lends itself well to other areas, presumably including screening. Is that something on your long-term roadmap?
Ozan Atay, CEO
Absolutely. I mean, if you think about tissue-free MRD and early detection, they are essentially equivalent problems. In fact, there are others where... In backbone, the same assay is being used for tissue-free MRD and early detection because the problem is the same. You don't know what the tumor is and what you are trying to do, you are trying to detect infinitesimal level of tumor in blood and differentiate someone who has cancer from someone who doesn't have cancer. So the problem statement, technical problem statement, is exactly the same for tissue-free MRD and early detection. So from that perspective, once you solve one of them, actually, you have solved the other problem as well. And that is why we are so excited about our nuclear launch, because it de-risks that potential for screening.
Doug Schenkel, Analyst — UBS
Okay. That's great. All right. So, we're going to come back to cancer in a few. I want to start on Unity as we talk about the different businesses. So, this is, for those who don't know, your blood-based prenatal screening portfolio. It includes single-gene fetal risk screening, and it anchors really the core, the major generator of revenue today. You grew, I think it was over 40% in the third quarter. So momentum continues to be strong. Building off of what we've already talked about, beyond panel breadth, what differentiates Unity Confirm and Fetal Risk Screen in terms of clinical evidence, reportable results, workflow, economics? How do you think about the differentiation and what matters most to clinicians?
Ozan Atay, CEO
You know, in terms of differentiation, it is all of them, right? In terms of the gross margin and the profitability of our prenatal business, it is completely unmatched, not just compared to other prenatal businesses, but in molecular diagnostics in general. It is the engine that allows us to invest so heavily into our growth, into our clinical studies, into our oncology, while staying profitable. But of course, from a clinician perspective, that is not what is the value for them. And there, I think, workflow has been a really critical differentiation for us. Because our single-gene NIPT is really the only single-gene NIPT that is designed for general population use, that intended use, where partner testing does not have to be done, that it makes that workflow so much easier. For, you know, all these physicians, but also there are unique components of this that serves different parts of the different stakeholders in the clinician journey. If you think about, you know, our fetal antigen in IPT, which is only about 0.5% of patients, but those are the highest risk patients where it can truly save lives. And if you think about from the perspective of a maternal fetal medicine specialist, they see more allo-immunized patients in that category than the high-risk patients or aneuploidies that they get referred to. So for them, it's a game changer. For them, it is more important than aneuploidy testing. So we get these very strong advocates. Due to different parts of the, you know, portfolio workflow that allow us to really, you know, bring in these accounts, because the maternal fetal medicine specialist who is getting referred patients is advocating for the test. And the OBs love the workflow of, you know, being able to have one test that cover not just all of their needs, but the needs after the patient is referred.
Doug Schenkel, Analyst — UBS
When you get that advocate on board. They presumably move everything over to you, right? You argue and demonstrate an advantage in a certain area. For the most part, that's going to lead to full capture of share in that account. Is that a reasonable way to think about it?
Ozan Atay, CEO
It usually is. You know, maternal fetal medicine specialists are so specialized that they might still rely on other tests for certain other indications, but you become the test that they tell their OBGYNs who are referring their high-risk patients to them to use us frontline. And that is why I think the expansion of unity fetal risk screen was so important, because we had OBGYNs who absolutely love the portfolio, the products that we offer, the workflow, covering ACOG-recommended conditions, the ease of use, and then the MFMs with the fetal antigen testing, unity confirm, game-changing products for them. But what we didn't have something that, you know, completed that portfolio with larger panels because we didn't even have a large carrier screening panel. Let alone, you know, fetal risk screening with the cell-free DNA for the baby. We weren't even testing the mother and the father in the traditional sense with large panels. And while that is not something that most OBGYNs, you know, would typically use in their practice, it is something that genetic counselors absolutely need because they take care of the rare conditions. And so when you are going into health system, Which is the, you know, a lot of the remaining value, remaining opportunity is in the health systems for us. We had a lot of the support from OBGYNs and MFMs and not always from genetic counselors when we didn't have these larger panels. And I think, you know, having now the full portfolio of products really make a big difference in advancing those companies.
Doug Schenkel, Analyst — UBS
In terms of competitive response, so Natera has expanded vehicle focus. They can bundle offerings. How's Unity positioned as Natera and other more established providers, you know, essentially respond to what you've brought to market?
Ozan Atay, CEO
I think part of this is that, you know, we... We have so many other advantages in addition to single gene and IPT that we continue to have a strong product advantage. But the other part is that we are the ones with peer-reviewed publications. And the last peer-reviewed publication, which is a prospective, multi-site, intended use population study, it was five years in the making. And that makes a difference when, you know, two products are trying to be positioned in the same way. But the other, you know, discussion that we have with providers is about, you know, those competitive products and how they are designed. Because they are designed primarily to look at, for instance, linked locations across the genome. They are not directly finding the causal variant. They are looking at the correlations. And that can actually become a problem if the partner testing is not done. So even the tests that are designed are not actually designed to truly match the use cases that we can offer.
Doug Schenkel, Analyst — UBS
From a guideline standpoint, when we think about single-gene fetal risk screening, there's still some evidence and access hurdles. How should we think about those?
Ozan Atay, CEO
So, in general, you know, the coverage is not really there, but because this is a reflex, this is a test that is done after the carrier testing, the fact that the insurance doesn't always cover it actually doesn't limit any of the access.
Doug Schenkel, Analyst — UBS
You still want to do this test.
Ozan Atay, CEO
Yeah, you still want to do this test. You know, it doesn't result in, you know, additional patient responsibilities or costs. And that is because we have designed this so that it can be accessible to every patient, regardless of their insurance, regardless of their socioeconomic status. And that is the beauty and the power of the QCT platform. But we can actually offer this broadly while being a profitable company, whereas I think it's very difficult for others to do the same. That said, you know, what we are really excited about, you know, in single gene and IPT is that, you know, if HAMA is in place, right, in January 1, 2027, single gene and IPT will get more than 100% increase in its clinical lab fee schedule. In the short term, without coverage, that might not mean a significant ASP lift.
Doug Schenkel, Analyst — UBS
But it's there.
Ozan Atay, CEO
But it is there. In the long term, if there is coverage, that can result in 20% revenue increase overall for the company that would become 20% profit margins as well.
Doug Schenkel, Analyst — UBS
So that's a good lead into my last unity question. So keeping in mind, prenatal revenue rose 42% in the quarter. Your gross margins are quite robust. As you think about some of the things we just talked about, Can you preserve the margin profile, and can the margin profile actually get better as mix evolves? Because there's some good guys and bad guys, but it does seem like, as you described things, and we think about the growth and where it's coming from, you might be able to preserve this margin, if not expand it.
Ozan Atay, CEO
Yeah, I think in prenatal, you know, we can not only preserve this margin but expand it, but we also are doing this. Truly with a long-term perspective. You know, I think there is this potential misunderstanding that every test volume, every test is equal to each other. Right. That is absolutely not the case. And I think, you know, if you truly take a kind of on the long-term perspective to this, there are going to be even accounts that you walk away from. And we don't see competitors doing that typically, whereas we take a very long-term view, and when we are making an investment, let's say that we are opening up a global-term service center to be able to access an account, we need to make sure that that has, you know, at least an ROI of 5 to 1 or 10 to 1. Whereas, you know, others might actually do that at negative margin. So we don't make those decisions, and I think that really allows our prenatal to have both growth, but the profitability, which we then can use for both growing our prenatal business and expanding our product portfolio and other things, but also invest in oncology and oncology's growth.
Doug Schenkel, Analyst — UBS
All right, so let's talk about North Star. So, this is your blood-based oncology portfolio. Select is therapy selection, response is treatment monitoring, and clear is your move into MRD. Um, and, um, This has been growing very robustly across the portfolio, obviously, from different starting points. Let's start overall for Northstar, and we've talked about the differentiation of the overall platform. But here, you're selecting profile. Basically, there's... You're looking at genomic alterations to inform therapy selection with select response, tracks treatment response through serial blood draws. What's different from the incumbents? I mean, some of it is what we talked about in terms of the technology. Are there other attributes we should be contemplating that are helping you win?
Ozan Atay, CEO
Of course, I think from a clinician perspective, Technology by itself doesn't matter as much. You know, it is about what that means for the patient and their patients. So with respect to therapy selection, you know, what we have been able to show with a head-to-head study, you know, against the incumbents, that we can detect 50% more actionable therapies. This is such a surprising number that sometimes physicians don't even believe us. Like, you know, they have been using these incumbents for years, and how can you come in and detect, you know, so many more actionable therapies? And, you know, are these real therapies? Do the patients respond to them? And what we have been able to do is actually to offer, you know, research pilots in these clinics themselves. So that they can see for themselves that we are truly better, and that the patients are responding to these things. So that, I think, not only creates a user, that creates an advocate. And, you know, really our growth in oncology is all about access. Once you have access, and once you can do these, you know, pilots, once you can prove that you are so much better, you are going to get physicians to switch them, because every patient who is sitting in front of them You know, has cancer, they are dying. They need better therapy. This is different from some of the prenatal discussions. In prenatal discussions, even if you have absolutely, you know, remarkable tests, and even if everything else is terrible, not that they are terrible, but even if they are, you know, you are maybe helping one out of 100 patients, right, that has that condition.
Doug Schenkel, Analyst — UBS
Yeah, every patient who's ordering.
Ozan Atay, CEO
Yeah, so it's like in cancer, it is different. It's like every patient needs a better test. So from that perspective, oncologists are actually a lot more passionate about the tests that they do, especially if you can show that you are differentiated, that you can offer their patients something better. And that is why I think, you know, as we are getting into more and more of these clinics, actually our biggest drivers become referrals from the physicians who experience that, and that opens up even more doors, and that is why we are seeing an acceleration of test volume growth.
Doug Schenkel, Analyst — UBS
And that's true of both select and response.
Ozan Atay, CEO
Certainly. I think there are actually a lot of synergies between select and response, right? They kind of see how powerful the response is, how it can detect the patient progressing even before scans. Then they might order another therapy selection test to see what might be driving that increase, change the therapy. So the combination actually becomes very powerful. Sometimes response becomes a wedge to get into an account, but then, you know, as they see that progression, they use a select test, or it might be the select head-to-head that gets you into account, but then response allows you to get repeat testing.
Doug Schenkel, Analyst — UBS
Understood. Interesting. All right, let's talk about CLEAR and your positioning in MRD. So, this is a tissue-free MRD test. It's scheduled to launch in a few weeks, right, December 15th? How do you think this is differentiated? I think I know what the answer is going to be, but we had an MRD panel yesterday, and one of the panelists... He was an evangelist for MRD. He loved it. He's been using it in his group, is using it in every cancer. They've been an early adopter. But, you know, he made the point, listen. Tumor-informed is always going to be better. There's logistical challenges, but it's always going to be better. It sounds like you believe this is positioned to close that gap, so maybe you can walk us through that.
Ozan Atay, CEO
Exactly. I think today, if you speak with oncologists, they have to make this tradeoff. There is the tumor-informed tests that are believed to be the kind of gold standard, more sensitive tests, but then logistical challenges, dealing with the tissue, turnaround time, QC fail rates become really a big issue. And they become, you know, bigger and bigger issue as you move away from colorectal cancer. You know, the primary use case of MRD today is in colorectal, right. You know, three, four, five years from now, other cancer types are probably going to be as big, if not bigger. In utilization. And in those other cancer types, it becomes an issue to use tumor-informed tests. If you see failure rates are higher, the turnaround time becomes a problem. And in some community oncology settings, they just logistically cannot deal with the tissue. So what we are finding is that tumor-informed market, I think, is going to get very competitive and in some ways commoditized. But if you can have a tissue-free test, Where you don't have to sacrifice the sensitivity. It becomes a game changer. Especially for community oncology settings where ease of use is so important. And that is 80% of where the eventual MRD utilization is going to be. So this is how we are positioning it. It is not about... We are not saying we are the... Best tissue free test. We are going beyond that. We are saying that, you know, you don't have to sacrifice the sensitivity. We have on par or better performance than, you know, some of these tissue informed tests that you have been relying on, you know, for years now.
Doug Schenkel, Analyst — UBS
How do you get people to understand? I think the clinicians are going to understand the concept. How do you build, how do you get more buy-in that you're the solution to this problem?
Ozan Atay, CEO
I think head to head is critical, right? I think, you know, we can, and we will need to generate, and we have been, you know, doing studies in the background across, you know, all these different cancer types that, you know, when we are saying that the patient is going to... You know, progress that they are going to progress. You know, we will need to be able to have, you know, great clinical outcomes and separation between, you know, patients who are ctDNA positive and ctDNA negative. But that's not going to be enough by itself, right? Because that's not, you know, no study is truly head-to-head. You know, so even if we have great clinical outcomes, it's not going to convince. The community, you know, the oncologist, that, you know, this is as good as their tumor-informed test. This is where I think head-to-head comes in. If you can show in head-to-head studies that this is on par or better than tumor-informed tests, I think that that becomes especially in, you know, for not everyone, but for the majority of the providers. The evidence that you need.
Doug Schenkel, Analyst — UBS
And of course, they are not going to trust you on day one.
Ozan Atay, CEO
They are going to try you. They are going to use you along with some tumor-informed test. They are going to see it for themselves. And we have already done that on the select side, though. Right? As we kind of have these publications, show the policy.
Doug Schenkel, Analyst — UBS
You're not afraid of doing the head-to-head.
Ozan Atay, CEO
No, we are not afraid to do any head-to-head.
Doug Schenkel, Analyst — UBS
All right. So that's the playbook. Origin is a tissue of origin prediction add-on to select. How important is that capability? And then going back to the question I asked about screening, I got to imagine there's some connection between this add-on and demonstrating your capabilities in different areas.
Ozan Atay, CEO
What we have found initially... We thought that tissue of origin is not a huge problem, right? We thought that, you know, looking at the literature, only 3% of patients should have this issue where they have truly an unknown primary, which is, you know, causing the oncologist not know how to treat the patient, and they tend to have, you know, much worse outcomes compared to when they know, you know, what the tissue of origin is. What we have found, though, is that, you know, in community oncology settings, The number is actually higher, because all of the studies are typically coming from, you know, more academic oncology, top institutions, where they have so much access to additional tests, great pathology workups, where, you know, yes, true, you know, tissue of unknown origin is 3%, but if you talk to community oncologists and see kind of uncertain diagnoses, it becomes closer to 10 to 15%. And 10 to 15% is large enough that if you ignore that population, it becomes difficult for them to use you as your primary test. So this is why we found that tissue of origin is a very important add-on for those patients where this makes a really big difference.
Doug Schenkel, Analyst — UBS
And, you know, we talked a little, you know, a lot about community oncology.
Ozan Atay, CEO
What I want to clarify here is also, you know, we actually get a lot of academic oncologists as well as community oncologists that are using our test, and both of them are very important. But what we find is that when academic oncologists are using us, they are sending us their most difficult cases. Whereas when community oncologists are using us, If they believe that they are going to be helpful to their most difficult cases, they will use you for the vast majority of their patients.
Doug Schenkel, Analyst — UBS
Yeah, they're not there. If anything, they want to do menu consolidation, right? A Q3 question. Oncology clinical testing revenue rose 96% to $17.1 million in the quarter. Have you disaggregated, you know, how much of that was select versus response? How much of it was new physician ads versus repeat testing? It's early, but have you spoken to any of those metrics?
Ozan Atay, CEO
So... I'm just going to do a quick math. We get about two response tests to one select test. Okay. But in terms of the revenue contribution, select ASP is close to five times of the response ASP. Okay. So from that perspective, I would say that, you know, probably, you know, you do the math like five to two ratio. In terms of where the revenue is, but that also shows the great opportunity with response.
Doug Schenkel, Analyst — UBS
Okay. 2027, I'm not gonna, I mean, I'd love if you've got, but that's not what I'm gonna ask, but how should, is there a framework we should think about in terms of how much growth we can get from prenatal versus oncology?
Ozan Atay, CEO
So I think, you know, in prenatal, You know, if we ignore any kind of big events like guideline changes or other things that can be, you know, full astronomical in terms of how much it would add, if we kind of ignore those things, if we ignore health systems, which is actually a bigger opportunity for us, you know, as we look at, you know, potentially next year, but in the long term. Even if you just look at the single specialty clinics and how much we can grow and how much we have been growing, I think, you know, prenatal, with some of the ASP improvements that we have seen as well, the contribution can get to still about 20% growth on that business without, you know, any of those potential additions that would come. Then oncology, I think, you know, test volumes are growing faster than 100% year over year, and we are seeing acceleration. So, you know, I think we will see. Similar growth in oncology, and that is not even taking into account, you know, clear as well as some of the ASP lifts that we might have for response. So I think as we get closer to the. Second half and, you know, end of 2027, actually more and more of the stories about oncology because the revenue contribution as well as the sequential growth will be very significantly oncology-oriented.
Doug Schenkel, Analyst — UBS
OPEX rose 56% in the third quarter. We should be thinking you're still very much in an operational investment phase well into next year. Fair?
Ozan Atay, CEO
I think it is fair. I think one of the kind of important notes about, you know, that growth is also we have become public about a year ago. So there are certainly some investments that we have to make for public company operations, you know, accounting, finance. Audits, all of those have to be significantly uplifted as part of the IPO. And we are continuing to invest in a lot of product launches, both across prenatal oncology, as well as a lot of oncology clinical studies. So I think we'll continue to invest, but we want to invest in a way that creates. You know, significant long-term value. You know, every investment that we make is not just, you know, ROI positive, but 5 to 1, 10 to 1 ROI positive, so that long-term, we are not just optimizing for growth, but we are optimizing for the combination of rapid growth and profitability.
Doug Schenkel, Analyst — UBS
And, you know, you can hold on to the gross margin, which on the reproductive side was north of 70. I think it was 71% in the quarter. Oncology is still. 45%, but with more reimbursement, that gets better. So with volume, with gross margin improvement, and seeing some return on the growth investments you're making at the OPEX line, you can see over time how this gets better.
Ozan Atay, CEO
I think prenatal is 75, oncology is 45, blended was 71. I don't know whether we are always going to be at 71 because oncology is growing faster. It is going to depend on prenatal's continued growth as well as the coverage decisions around response and how fast MRD scales. But the good thing about all of this is that We realize that even if the gross margin in the short term has one or two percentage point decreases, that is going to be really good news because that means that oncology is growing even faster than projected, and it's not going to impact the bottom line profitability because of the cost structure of our product. So, you know, as opposed to many other MRD products here, you know, MRD, even by the end of first year, should have around, you know, close to gross margin break-even. So, that is not going to result in, you know, negative profitability.
Doug Schenkel, Analyst — UBS
That's a burn, right? That's not happening. I know we're out of time. That being said, if we're sitting here a year from now, what do you think we're going to point to that was the biggest thing the investment community is missing on billion to one? Could be one year, could be three years.
Ozan Atay, CEO
I think in the long term, what is really... I don't know whether this is missing, but these are marked both in the tissue-free MRD response monitoring and early detection, where having the combination of a tissue-free approach. And the sensitivity is critical. These are markets where it is going to take time. It's not going to be turning overnight. But over long term, I think the winners are going to be the companies that can grow rapidly, combine it with profitability, whether any of the volatility in the markets so that they can continue to invest and have the best products, not necessarily the ones that are first to market.
Doug Schenkel, Analyst — UBS
All right. Let's leave it there. That's great. We really appreciate the time. Thank you.
Ozan Atay, CEO
Thank you.